Yoh U. Matsuoka

Saitama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 131 publications

Prognostic Value of Inflammatory Biomarkers as Continuous Variables in Metastatic Renal Cell Carcinoma: Linearity Assessment, Proportional Hazards Assumption Testing, and Time-Varying Effects.

Prognostic Value of Inflammatory Biomarkers as Continuous Variables in Metastatic Renal Cell Carcinoma: Linearity Assessment, Proportional Hazards Assumption Testing, and Time-Varying Effects.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: April 04, 2026

Real-World Outcomes of Olaparib Treatment in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA Pathogenic or Likely Pathogenic Variants.

Real-World Outcomes of Olaparib Treatment in Japanese Patients With Metastatic Castration-Resistant Prostate Cancer Harboring BRCA Pathogenic or Likely Pathogenic Variants.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: April 03, 2026

External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinations.

External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinations.

Journal: International urology and nephrology

Published: March 15, 2026

Active surveillance for patients with prostate cancer aged ≥75 years: the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study.

Active surveillance for patients with prostate cancer aged ≥75 years: the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study.

Journal: BJU international

Published: January 29, 2026

Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer.

Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer.

Journal: Japanese journal of clinical oncology

Published: January 22, 2026

Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer.

Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer.

Journal: Anticancer research

Published: January 08, 2026

Diagnostic value of MRI-ultrasound fusion-targeted prostate biopsy for non-index lesions combined with the index lesion biopsy.

Diagnostic value of MRI-ultrasound fusion-targeted prostate biopsy for non-index lesions combined with the index lesion biopsy.

Journal: Urologic oncology

Published: October 16, 2025

Mixed Response to Nivolumab Among Different Metastatic Sites in Patients With Metastatic Renal Cell Carcinoma: Incidence and Clinical Implications.

Mixed Response to Nivolumab Among Different Metastatic Sites in Patients With Metastatic Renal Cell Carcinoma: Incidence and Clinical Implications.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: October 04, 2025

Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective multicenter study.

Clinical outcomes of retreatment or discontinuation after interruption of nivolumab plus ipilimumab due to immune-related adverse events in metastatic renal cell carcinoma patients: A retrospective multicenter study.

Journal: Urologic oncology

Published: March 23, 2025

Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.

Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: March 06, 2025

Editorial Comment to "Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer".

Editorial Comment to "Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer".

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: February 14, 2025

Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study.

Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: January 12, 2025

Showing 1-12 of 131

Last Updated: 09/26/2026